T2 Biosystems Gains FDA Nod for Pediatric Sepsis Test

The latest announcement is out from T2 Biosystems ( (TTOO) ).

T2 Biosystems has announced FDA clearance for its T2Candida Panel for use in pediatric patients, positioning the company to immediately start marketing this rapid diagnostic tool to over 200 children’s hospitals across the U.S. This panel, which detects sepsis-causing Candida directly from blood samples in 3-5 hours, is a significant improvement over traditional blood cultures, which take days. It has been recommended for diagnosing invasive candidiasis in at-risk youth, as it offers faster detection and higher sensitivity, potentially reducing hospital stays and associated healthcare costs.

See more data about TTOO stock on TipRanks’ Stock Analysis page.